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EditorialThe Phase 3 Study ECHELON-1 Evaluating
Brentuximab Vedotin in Patients With Newly
Diagnosed Hodgkin Lymphoma Leaves Important
Questions Unanswered
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published phase I results of brentuximab vedotin (BV), an
antibody-drug conjugate targeting CD30.1 After decades of
standstill in the commercial development of new drugs in
Hodgkin lymphoma (HL), this pioneering innovation opened up
new options in this malignancy affecting mainly young adults.
Phase II results of BV in relapsed or refractory (r/r) classical HL
(cHL) then revealed an exceptional overall response rate of 75%,
which led to approval.2 This was the first study reporting only
positron emission tomography (PET)-based response rates,
which were not comparable to results from all previously
published studies using computed tomography (CT)-based
response assessment. The more relevant progression-free survival
(PFS) was less impressive with a median of 5.6 months.
Subsequently, BV has been widely used as “bridge-to-transplant”
for r/r HL patients. A phase 3 study then proved the activity of
single-agent BV as consolidation after high-dose chemotherapy.3
In this setting, cHL patients treated with BV for 1 year had a
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patients based on trials without any active comparator.
Nonetheless, the idea of using a targeted drug with high
efficacy and good tolerability for cHL is attractive and BV might
also be a promising drug to improve the treatment of newly
diagnosed cHL. This is especially true for patients with advanced-
stage disease. Here, 6 to 8 cycles of ABVD (doxorubicin,
bleomycin, vinblastine and dacarbazine) used to be the standard
of care inmany countries. ABVD can be safely administered in the
outpatient setting and is rather inexpensive. However, this
regimen clearly needs improvement in terms of efficacy. This was
and still is attempted either by early PET-based selection of poor
responders and subsequent treatment intensification or by
introducing new drugs.4 The respective phase II trial combined
BV with ABVD or AVD to set the ground for a phase III study.
Unfortunately, 2 patients in this trial treated with BV plus ABVD
died due to lung toxicity of the combination of BV and
bleomycin.5 The sponsor then decided to test the regimenwithout
bleomycin in the BV+AVD regimen (BV, doxorubicin, vinblas-
tine, and dacarbazine). Lung toxicity was less pronounced and
this regimen was selected to challenge ABVD in the ECHELON-1
prospectively randomized phase III trial.6
It is important to remember that the development of the BV+A
(B)VD regimen was driven by the idea to challenge ABVD in an
add-on design, which obviously could have been an elegant way
to show its efficacy in a company-sponsored pivotal study.
Unfortunately, the active compound of BV, monomethyl
auristatin E (MMAE), is a microtubule inhibitor, similar to
vinblastine being a pivotal part of the A(B)VD regimen.
Microtubule inhibitors usually have a rather narrow therapeutic
window, which is especially true forMMAE. Oncologists usually
do not use higher doses of microtubule inhibitors or combine 2
microtubule inhibitors. This is because one should expect a steep
increase of dose-dependent toxicity, especially neutropenia and
neuropathy without a comparable increase in efficacy. Despite
such considerations, the combination of BV (MMAE) and
vinblastine in the BV-AVD regimen was tested in the experimen-
tal arm of the ECHELON-1 study.
The NEJM published the ECHELON-1 data by Connors and
colleagues and the results were also shown in the plenary session
of the 2017 ASHmeeting.6,7 The authors reported a total of 1334
patients with previously untreated stage III or IV cHL, of whom
664 were assigned to BV+AVD and 670 to ABVD. The primary
Editorial Editorialendpoint was modified progression-free survival (mPFS), defined
as the time to progression, death, or noncomplete response and
use of subsequent anticancer therapy as adjudicated by an
independent review committee. Two-year mPFS rates in the BV+
AVD and ABVD groups were 82.1% (95% confidence interval
[CI], 78.7–85.0) and 77.2% (95% CI, 73.7–80.4), respectively,
with a difference of 4.9% points (hazard ratio [HR] 0.77; 95%CI
for HR, 0.60–0.98; the originally published P value=0.03 was
corrected to 0.04 in an erratum published inMarch 2018,NEngl
J Med 2018; 378:878). Based on the significant difference, the
authors concluded that BV+AVD “had superior efficacy to
ABVD in the treatment of patients with advanced-stage Hodgkin
lymphoma.”
Many questions arise with the publication of this company-
sponsored study in patients with newly diagnosed cHL. First, the
primary endpoint mPFS introduced in this study has not been
established in clinical research. In contrast to the well-established
endpoint PFS, which evaluates time to disease progression or
death, mPFS is per definition subject to bias, counting optional
additional anticancer treatment including radiotherapy as a
failure event. ECHELON-1 was an unblinded study in that
physicians knew whether their patients received ABVD or the
new BV+AVD treatment. In case of non-CR at the end of
treatment, this could have impacted the decision on whether
additional therapy was needed. These considerations clearly
reflect the vulnerability of mPFS to bias indicating the weakness
of this endpoint. The medical community relies on relevant
established endpoints to put results of clinical trials such as
ECHELON-1 into perspective. So far, this information has not
been delivered. Looking at the numbers reported in the
manuscript, the difference in terms of mPFS seems moderate
(117 vs 146 events for BV+AVD and ABVD, respectively). A
considerable proportion of mPFS events are in the category
“noncomplete response and use of subsequent anticancer therapy
as adjudicated by an independent review committee” (9 vs 22,
respectively), and only 2 and 4 of these mPFS events were
confirmed as PFS events by the independent review committee
(see Table 1). It thus seems likely that the actual PFS difference is
smaller than the mPFS difference and might even miss statistical
significance.
In addition, other questions regarding the primary endpoint in
the ECHELON-1 trial should be addressed: the study was
originally designed to show a 7.5% difference (82.5% vs 75%,
HR 0.67) in favor of the BV+AVD regimen at 3 years with 1040
patients. However, the study was amended in order to evaluate
the primary endpoint at 2 years already. According to this
amendment, 1240 patients would have been needed to show a
mPFS difference of 8% (HR 0.67), assuming a mPFS of 73% at 2
years for ABVD, which is less than initially assumed for 3 years.Table 1
mPFS and IRC-Confirmed PFS Events in ECHELON-1
Category
Progression
Death
Noncomplete response and use of subsequent anticancer therapy as adjudicated by an ind
Confirmed as PFS event by IRC
Not confirmed as PFS event by IRC
mPFS events
IRC-confirmed PFS events
ABVD=doxorubicin, bleomycin, vinblastine, and dacarbazine, AVD=doxorubicin, vinblastine, and dac
progression-free survival.
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Finally, 1334 patients were evaluable for the primary endpoint.
Thus, the study was obviously over-recruited and the relevance
of the P value should be judged with caution. We can safely
conclude that the difference was smaller than expected (observed
4.9%, expected 8%; HR observed 0.77, HR expected 0.67).
Therefore, we should discuss whether the moderate statistically
significant benefit in terms of mPFS at 2 years is actually clinically
relevant. This depends critically on 2 major parameters: the long-
term outcome, which we obviously do not know yet, and the risk-
to-benefit ratio of the new regimen, which the authors did not
discuss adequately.
When observing a moderate benefit for a vulnerable primary
endpoint, the experimental regimen could still be beneficial for
the patient if it was better tolerated. However, the opposite is true
for ECHELON-1: with the exception of severe lung toxicity,
which occurred at rather low levels with both regimens (<1% vs
3% for BV+AVD vs ABVD, respectively); all other reported
adverse events (AEs) were clearly more frequent with BV+AVD.
This is true for severe toxicities ≥ grade 3 (83% vs 66%), serious
AEs (43% vs 27%), hospitalizations (37% vs 28%), and others.
In particular, severe neutropenia and severe neuropathy occurred
more often with BV+AVD containing 2 microtubule inhibitors.
This raises doubts on the usefulness of the experimental regimen.
Grade 2 or higher peripheral neuropathy can be a disabling AE,
which should be particularly avoided in these young HL patients.
Overall, 30% of BV+AVD-treated patients suffered from
neurotoxicity of at least grade 2. Unfortunately, the authors
did not report on the persistence of neuropathy. We can only
speculate how well neuropathy will resolve to a clinically
acceptable degree. Clearly, the community needs exact numbers
on frequency and severity of neuropathy to be reported at 2 years.
All these numbers suggest that the risk-to-benefit ratio for BV+
AVD is not convincing. We strongly believe that treatment-
related risks should be taken into account,8 especially when there
is no convincingly demonstrated benefit in terms of relevant
endpoints such as PFS or overall survival.
Regarding the disadvantage of BV+AVD in terms of
tolerability, the presented information (or better, the lack of
such) and the corresponding conclusions also raise concern. For
example, the authors conclude that BV+AVD is “a safe and at
least equivalently effective treatment for older patients compared
to ABVD.” However, older patients did not benefit from BV+
AVD at all (HR=1.0 [0.6–1.7]). Since neuropathy and
neutropenia are usually more common and pronounced in
elderly patients, there might be a particular risk in this cohort
receiving treatment with BV+AVD. The authors did not report
data that would either support or disprove this part of their
conclusion. However, the frequency of CTCAE grade 3 to 4
neutropenia in BV+ABVD arm should be mentioned at this pointA+AVD (N=664) ABVD (N=670)
90 (13.6%) 102 (15.2%)
18 (2.7%) 22 (3.3%)
ependent review committee 9 (1.4%) 22 (3.3%)
2/9 4/22
7/9 18/22
117 (17.6%) 146 (21.8%)
110 (16.6%) 128 (19.1%)
arbazine, IRC= independent review committee, mPFS=modified progression-free survival, PFS=
Table 2
Outcome Data of Standard-of-Care-Defining Studies in Advanced-Stage HL
N
3-Year
PFS All, %
3-Year
PFS Stage III/IV, %
3-Year
OS All, %
3-Year OS
Stage III/IV, %
3-Year Cum.
Incidence SN, %
TRM,
%
Grade III/IV
AEs, %
HD18 PET-positive, 6 eBEACOPP 506 92.0 92.2 98.0 98.0 4.1 0 95.2
PET-negative, 4 eBEACOPP 501 94.8 94.6 98.7 98.5 1.6 0 91.4
All (full ITT, 4–8 eBEACOPP)a 2073 92.3 92.2 96.9 96.8 2.8 0.8 94.5
N
3-Year
PFS All, %
3-Year
PFS Stage III/IV, %
3-Year
OS All, %
3-Year OS
Stage III/IV, %
SN After
41 Months
MOT, %
TRM,
%
Grade III/IV
AEs, %
RATHL PET-positive, 2 ABVD+4
eBEACOPP or +6 BEACOPP-14
172 67.5 63.9 87.8 87.8 1.7 2.3b ≥80–83 (information
for cycles 3–8 only)
PET-negative, 2 ABVD+4 AVD 465 84.4 82.1 97.6 97.8 2.4 0 ≥65 (information
for cycles 3–6 only)
All eligible patients (2 ABVD+4
ABVD, AVD, eBEACOPP, or 6
BEACOPP-14, respectively)
1203 82.6 79.8 95.8 94.6 2.4 0.7b ≥64 (information
for cycles 1–2 only)
N
2-Year mPFS
Stage III/IV, %
2-Year OS
Stage III/IV, %
2-Year Cum.
Incidence SN, %
TRM,
%
Grade III/IV
AEs, %
E-1c BV+AVD 664 82.1d 96.6 Not reported 1.2b 83
ABVD 670 77.2d 94.9 Not reported 1.0b 66
ABVD=doxorubicin, bleomycin, vinblastine, and dacarbazine, AE= adverse event, AVD=doxorubicin, vinblastine, and dacarbazine, BV=brentuximab vedotin, HL=Hodgkin lymphoma, ITT= intention-to-treat,
mPFS=modified progression-free survival, OS= overall survival, PET=positron emission tomography, PFS=progression-free survival, TRM= treatment-related mortality.
a Includes patients treated with 8 (Rituximab+ )eBEACOPP.
b Includes pts>60 years.
c Only 2-year data available.
d mPFS includes additional failure events as compared with PFS.
(2018) 2:3 www.hemaspherejournal.com—it occurred originally in 73%of the patients and led to protocol
amendment implementing primary mandatory G-CSF prophy-
laxis. Another example of conclusions made without presenta-
tion of relevant data is the discussion of neurotoxicity, stating
that the BV+AVD regimen “is associated with more [ . . . ]
neurotoxicity (which is largely reversible) than ABVD but
substantially less pulmonary toxicity.” While valid data on
reversibility of neurotoxicity are not presented in the manuscript
as described above, a substantial decrease of severe pulmonary
toxicity can hardly be stated given the low level of 3% for ABVD
in this trial. Taken together, the risk-to-benefit ratio of this new
regimen cannot be discussed without sound data.
Finally, the presentation of study results ignores the current
standard of care, which is individualized, response-adapted
therapy guided by early PET. The authors do not even mention
the RATHL trial in their discussion, which has recently
established PET-guided ABVD in the treatment of advanced-
stage HL. The disregard of current standards also includes PET-
guided eBEACOPP (dose-intensive courses of bleomycin, etopo-
side, doxorubicin, vincristine, procarbazine, and prednisone),
which is used as standard of care inmany European countries and
is clearly more effective than BV+AVD (see Table 2).9
In summary, the ECHELON-1 trial raises concern for many
reasons. First, the primary endpoint mPFS is subject to bias per
definition. This problem could be overcome by presenting PFS
data. Reported numbers suggest that there is no relevant PFS
difference, but full data are needed to judge the potential benefit
of the new regimen. Second, taking into account the marginal
increase in efficacy, the obvious increase of toxicity needs to be
presented in detail in order to balance risks and benefits of the BV
+AVD regimen. Third, treatment of HL has evolved while the
ECHELON-1 study was recruiting. Today, response-adapted
therapy based on early PET-CT has become standard of care and
allows tailoring the treatment intensity to the individual patient’s
need. Exposing 100%of patients to a treatment with clearlymore3
AEs in order to achieve a minor (<5%) and questionable (mPFS)
benefit seems to be an outdated strategy. Finally, the disregard of
current standards in the presentation and discussion of
ECHELON-1 does not support the academic discourse, which
is essential to find the best way to treat our patients. The history
and success of academic clinical research in HL reflects the huge
potential of this academic discourse.
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